Physician profile
Terrence Mcgrath
NPI 1326434341
$623.55
in general payments reported to CMS, 2019-2025
18 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $286 · 2020: $110 · 2021: $28.13 · 2022: $162 · 2023: $16.02 · 2024: $21.92.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $37.94.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $37.94 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Sanofi-Aventis U.S. LLC | $109.29 | 2019-2022 | |
| Amgen INC. | $85.95 | 2019-2020 | |
| Dexcom, INC. | $55.97 | 2022-2023 | Dexcom G6 Transmitter |
| Novo Nordisk INC | $47.62 | 2019-2022 | |
| Abbott Laboratories | $33.67 | 2022 | |
| Lilly USA, LLC | $32.25 | 2019-2022 | |
| Genentech USA, INC. | $31.86 | 2019 | |
| Janssen Pharmaceuticals, INC | $30.48 | 2019 | |
| Astellas Pharma US INC | $28.25 | 2020 | |
| Abbvie INC. | $28.13 | 2021 | |
| Astrazeneca Pharmaceuticals LP | $23.46 | 2019 | |
| Otsuka America Pharmaceutical, INC. | $23.09 | 2022 | |
| Exact Sciences Corporation | $21.92 | 2024 | Cologuard Collection Kit |
| Takeda Pharmaceuticals U.S.A., INC. | $18.27 | 2019 | |
| Amarin Pharma, INC. | $15.13 | 2019 |
Show all 18 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Bayer Healthcare Pharmaceuticals INC. | $13.13 | 2022 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $12.89 | 2020 | |
| Glaxosmithkline, LLC. | $12.19 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Terrence Mcgrath listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.